The ACRF Tumour Metabolism Laboratory – part of the ACRF Centenary Cancer Research Centre – has been officially launched with the laboratory sporting the latest in advanced equipment and technology to help support its innovative cancer research. Cancer is the second leading cause of death globally.
The laboratory, established by a $2.5M grant from Australian Cancer Research Foundation (ACRF) and in collaboration with the Centenary Institute, is dedicated to the study of tumour cell metabolism, at a molecular level. The team then utilise this knowledge to develop new cancer diagnostics, treatments and cures.
“Cancer cells, like all the cells in our body, require nutrients from our diet to survive and to flourish,” says Professor Philip Hogg, Deputy Director, Centenary Institute and Head, ACRF Centenary Cancer Research Centre.
“While our healthy cells mostly produce energy from these nutrients, cancer cells use them to suit their malignant purpose – which is to divide as rapidly as they can. They aggressively soak up the nutrients in their environment and convert them into the components of new cancer cells – that is DNA, protein and lipids. The focus of this laboratory is to understand how cancer cells change their metabolism. If we can successfully stop the cancer cells from changing their metabolism then we can use this knowledge as a basis for developing exciting new anti-cancer therapies.”
The state-of-the-art equipment available to the researchers at the ACRF Tumour Metabolism Laboratory allows for the precise measurement – down to the nanoscale – of the sugars, proteins and lipids that are consumed by the cancer cells.
“ACRF is delighted to have backed this program which will return significant research findings. Our support, through the provision of equipment for the research has been supplemented by a collaborative funding arrangement with Cancer Institute NSW who have assisted with complementary funding for research personnel. We so value the work that Professor Hogg and his team do to help deliver our supporters’ ambition to Outsmart Cancer,” says Kerry Strydom, CEO, Australian Cancer Research Foundation.
Pictured: Mr Tom Dery AO, Chairman ACRF (left) and Prof Phil Hogg, Head ACRF Centenary Cancer Research Centre (right).
Read the full media release here.
Professor John Rasko AO has led a world-first clinical trial into engineered stem cell treatment use, treating 15 patients with steroid resistant acute graft-versus-host disease.
Centenary Institute research has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.
Research led by the Centenary Institute has shown that a healthy weight and coffee consumption may help lower the risk of high-risk drinkers developing alcohol-induced cirrhosis.